Detalhe da pesquisa
1.
Bilateral Focused Ultrasound Thalamotomy for Essential Tremor (BEST-FUS Phase 2 Trial).
Mov Disord
; 36(11): 2653-2662, 2021 11.
Artigo
Inglês
| MEDLINE | ID: mdl-34288097
2.
Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient-related factors and measuring from time of first red blood cell transfusion dependence: an MDS-CAN analysis.
Br J Haematol
; 179(1): 83-97, 2017 10.
Artigo
Inglês
| MEDLINE | ID: mdl-28677895
3.
A predictive model of response to erythropoietin stimulating agents in myelodysplastic syndrome: from the Canadian MDS patient registry.
Ann Hematol
; 96(12): 2025-2029, 2017 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-28975386
4.
Patient-related factors independently impact overall survival in patients with myelodysplastic syndromes: an MDS-CAN prospective study.
Br J Haematol
; 174(1): 88-101, 2016 07.
Artigo
Inglês
| MEDLINE | ID: mdl-26991631
5.
The management and outcomes of patients with myelodysplastic syndrome with persistent severe thrombocytopenia: An observational single centre registry study.
Leuk Res
; 76: 76-81, 2019 01.
Artigo
Inglês
| MEDLINE | ID: mdl-30580105
6.
Lenalidomide and metronomic melphalan for CMML and higher risk MDS: a phase 2 clinical study with biomarkers of angiogenesis.
Leuk Res
; 38(7): 756-63, 2014 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-24819395
7.
Income and outcome in myelodysplastic syndrome: the prognostic impact of SES in a single-payer system.
Leuk Res
; 37(11): 1495-501, 2013 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-24095584